Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Aug 19, 2011 (rev. 1)


The Swiss Institute of Bioinformatics has tapped Selventa's CEO David de Graaf and Alexey Nesvizhskii, an assistant professor at the University of Michigan, Ann Arbor, to serve on its scientific advisory board.

Prior to joining Selventa, de Graaf served as the vice president of biotherapeutics and integrative biology at Boehringer-Ingelheim. He has also held positions at Pfizer, AstraZeneca, and the Whitehead Institute's Center for Genome Research.

De Graaf completed a postdoctoral fellowship at the Weizmann Institute of Science in Rehovot, Israel, in pharmacogenomics of human olfactory systems. He also earned a PhD in mammalian genetics from the University of Illinois, Chicago, and an MS in evolutionary genetics from the University of Utrecht in the Netherlands.

Nesvizhskii’s research interests lie in the field of quantitative proteomics, with a focus on developing computational methods for processing and extracting biological information from complex proteomic datasets. His lab develops computational tools and statistical methods for mass spectrometry-based peptide and protein identification and quantification; works on establishing guidelines and standards for proteomic data analysis and publication; and creates public databases and proteomic data repositories.

He received an MS from St. Petersburg State Technical University and a PhD in physics from the University of Washington, Seattle. He also completed a postdoctoral program at the Institute for Systems Biology.

Nesvizhskii and de Graaf were appointed to the board on July 1 by the SIB Foundation Council during the group's annual meeting.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.